Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Director comp.
Appointed director
23andMe Holding Co. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
10/06/2023 4 HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.
Txns: Sold 38,548 shares @ $0.8407, valued at $32.4k
Exercised 38,548 options to buy @ $0.42, valued at $16.2k
10/05/2023 144 Form 144 - Report of proposed sale of securities:
08/25/2023 4 HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.
Txns: Sold 40,894 shares @ $1.0544, valued at $43.1k
Exercised 40,894 options to buy @ $0.42, valued at $17.2k
08/24/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 4 HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.
Txns: Paid exercise price by delivering 4,628 shares @ $1.14, valued at $5.3k
08/22/2023 4 Selsavage Joseph Anthony (Interim CFO) has filed a Form 4 on 23andMe Holding Co.
Txns: Paid exercise price by delivering 6,209 shares @ $1.14, valued at $7.1k
08/22/2023 4 Richards William G (Head of Therapeutics Discovery) has filed a Form 4 on 23andMe Holding Co.
Txns: Paid exercise price by delivering 8,185 shares @ $1.14, valued at $9.3k
08/16/2023 4 HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.
Txns: Sold 40,894 shares @ $1.319, valued at $53.9k
Exercised 40,894 options to buy @ $0.42, valued at $17.2k
08/11/2023 3 Richards William G (Head of Therapeutics Discovery) has filed a Form 3 on 23andMe Holding Co.
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "23andMe Reports FY2024 First Quarter Financial Results Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit Webcast at 4:30 pm ET, August 8, 2023 SOUTH SAN FRANCISCO, Calif., August 8, 2023"
08/04/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
07/31/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/27/2023 144 Form 144 - Report of proposed sale of securities:
07/26/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
07/26/2023 ARS Form ARS - Annual Report to Security Holders:
07/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/30/2023 4 HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.
Txns: Sold 40,894 shares @ $1.7223, valued at $70.4k
Exercised 40,894 options to buy @ $0.42, valued at $17.2k
06/29/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 8-K Cost Associated with Exit or Disposal Activities  Interactive Data
06/07/2023 4 HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.
Txns: Granted 43,659 shares @ $0
Paid exercise price by delivering 15,098 shares @ $2.08, valued at $31.4k
06/07/2023 4 Hillan Kenneth J. (Chief Therapeutics Officer) has filed a Form 4 on 23andMe Holding Co.
Txns: Granted 44,381 shares @ $0
Paid exercise price by delivering 15,347 shares @ $2.08, valued at $31.9k
06/07/2023 4 Selsavage Joseph Anthony (Interim CFO) has filed a Form 4 on 23andMe Holding Co.
Txns: Granted 37,808 shares @ $0
Paid exercise price by delivering 13,075 shares @ $2.08, valued at $27.2k
05/25/2023 10-K Annual Report for the period ended March 31, 2023
05/25/2023 8-K Quarterly results
Docs: "23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 -- 23andMe Holding Co. , a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter and full year of fiscal year 2023 , which ended March 31, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration authorizations for over-the-counter genetic health risk reports. The Company has also created the world’s largest, re-contactable crowdsourced platform of genotypic information paired ..."
05/23/2023 4 Selsavage Joseph Anthony (Interim CFO) has filed a Form 4 on 23andMe Holding Co.
Txns: Paid exercise price by delivering 6,209 shares @ $1.94, valued at $12k
05/23/2023 4 Hillan Kenneth J. (Chief Therapeutics Officer) has filed a Form 4 on 23andMe Holding Co.
Txns: Paid exercise price by delivering 4,628 shares @ $1.94, valued at $9k
05/23/2023 4 HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.
Txns: Paid exercise price by delivering 4,628 shares @ $1.94, valued at $9k
04/17/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
03/02/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy